NCT02375555View on ClinicalTrials.gov

Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 7, 2015

Primary Completion Date

December 15, 2021

Study Completion Date

January 26, 2024

Conditions
Multiple Myeloma
Interventions
DRUG

Lenalidomide

DRUG

Elotuzumab

DRUG

Bortezomib

DRUG

Dexamethasone

PROCEDURE

Stem Cell Mobilization

Trial Locations (7)

22031

Virginia Cancer Specialists, Fairfax

28204

Levine Cancer Institute, Charlotte

30322

Emory University, Atlanta

63110

Washington University School of Medicine, St Louis

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

07601

Hackensack University Medical Center, Hackensack

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER